ABT

Abbott Laboratories 10-Q Summary: Quarter Ended September 30, 2007

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2007, and the nine-month period ended on the same date. Abbott Laboratories is a global healthcare company operating through four reportable segments: Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The company is a large accelerated filer with approximately 1.55 billion common shares outstanding as of the reporting date.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14.4% in the third quarter and 15.0% for the nine months compared to 2006. Growth was driven by acquisitions (Guidant and Kos Pharmaceuticals), unit growth, and a weaker U.S. dollar.
• Segment Performance:
  • Pharmaceuticals: Sales up 19.6% (Q3) and 17.8% (9M), led by HUMIRA and Niaspan.
  • Vascular Products: Sales up 14.9% (Q3) and 80.0% (9M) due to the Guidant acquisition.
  • Nutritionals: Sales up 4.4% (Q3) but down 1.4% (9M), impacted by the completion of the Synagis co-promotion in 2006.
• Profitability: Operating earnings rose 34.4% in Q3 and 33.3% for the nine months. However, gross margins declined slightly (55.1% vs. 57.1% in Q3) due to generic competition (Omnicef, Biaxin) and increased amortization of intangibles.
• One-Time Items:
  • GE Transaction Termination: Abbott terminated the agreement to sell its core laboratory diagnostics business to GE. Consequently, approximately $99 million of previously suspended depreciation and amortization was reinstated in Q3 2007.
  • Contract Termination: A $92 million charge was recorded in SG&A expenses in Q3 for terminating a contract.
  • Boston Scientific Investment: A $35 million fair market value loss was recorded in Q3 (and $136 million for the nine months) related to the investment in Boston Scientific common stock.

Guidance, Outlook, and Risks

• Outlook: Management expects annual cash flow from operating activities to continue to exceed capital expenditures and cash dividends. No specific forward-looking financial guidance for the full year 2007 is provided in this text.
• Acquisition Integration: Significant net cash inflows from Guidant's vascular products are expected to commence within one to two years of product launch (2008–2013). Kos Pharmaceuticals' cholesterol drug (Niaspan) is already contributing to sales.
• Legal and Regulatory Risks:
  • Pricing Litigation: Abbott faces civil actions and investigations regarding average wholesale price reporting for Medicaid/Medicare drugs. While reserves are recorded for some matters, the company cannot estimate losses for others, noting potential material impact on quarterly cash flows.
  • Patent Disputes: Ongoing litigation regarding Depakote and other products. Abbott recently secured an injunction against a generic version of Depakote.
  • Environmental: Aggregate cleanup exposure is estimated not to exceed $15 million.
• Capital Allocation: Abbott purchased approximately 19.0 million shares of its common stock for $1.0 billion during the first nine months of 2007. The company maintains $7.0 billion in unused lines of credit.

Investor Verification Checklist

• GE Transaction Impact: Verify the long-term strategic implications of retaining the core laboratory diagnostics business and the $99 million expense impact on future quarters.
• Patent Expirations: Monitor the timeline for generic competition on key drugs like Omnicef and Biaxin, which are currently eroding margins.
• Boston Scientific Exposure: Review the valuation and liquidity of the Boston Scientific stock investment and the associated derivative liabilities.
• Acquisition Synergies: Assess the progress of the Guidant and Kos Pharmaceuticals integrations against projected cost-to-complete estimates ($510 million for Guidant, $78 million for Kos).
• Legal Reserves: Scrutinize the adequacy of the $215 million legal reserve given the uncertainty surrounding pricing litigation outcomes.